Home
Methods The
Liver VA
News
AASLD ( American Association for the Study of Liver Diseases)
November 9-13, 2001, Dallas
Menopause May Accelerate Liver
Fibrosis; Perhaps Hormone Replacement Therapy Can Be Helpful
abstract 195. IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE
ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C
|
| |
| |
Vincent Di Martino,
Pascal Lebray, Joseph Moussalli, GH Pitie-Salpetriere and Reseau VHC
Paris-Sud, Paris France; Catherine Buffet, HTMpital Bicetre et Reseau
VHC-Paris Sud, Kremlin-Bictre France; Thierry Poynard, GH
Pitie-Salpetriere and Reseau VHC Paris-Sud, Paris France
program abstract:
During chronic hepatitis C (CHC), liver fibrosis progression is faster
in males than in females. Among all the factors involved in such
difference, estrogenes may be a major one since experimental data
recently supported that estrogenes may have direct antifibrosing
effect. The aim of this work was to evaluate the influence of
pregnancies, oral contraceptives and menopause on liver fibrosis (F)
and fibrosis progression rate (FPR) in HCV-infected women, taking into
account confusing factors such as age, alcohol consumption, and BMI.
Patients and methods: 472 women with CHC without HBV nor HIV
coinfection received an anonymous questionnaire that asked for alcohol
and tobacco consumption, presence of diabetes, age at first
menstruation, age at pregnancies with or without children, hormonal
contraception, age at menopause and its cause if any, and hormonal
substitution. These data were completed by those collected in the
DOSVIRC database. Liver biopsies performed before antiviral therapy
were analyzed using the METAVIR scoring system. The FPR was estimated
in case of known date of HCV infection and expressed in milli METAVIR
Units of fibrosis per year. Statistical analyses were performed using
Kruskall-Wallis rank test and logistic and multiple linear regression
models for multivariate analyses.
Results: 212 (44%) women completed the questionnaire. 192 (481 years
old) underwent adequate liver sample, among whom 99 had 1 to 7
pregnancies (0 to 5 children) during 151 months, 86 received oral
contraceptive(s) during 314 months, 95 had menopause 111 years
before liver biopsy, and 47 received hormonal substitution during 71
years. Only one woman had alcohol intake more than 50g/d. In
univariate analysis, F score and/or FPR were significantly lower in
women who had one or more pregnancies, who received hormonal
contraception, who were seen before menopause or who received hormonal
substitution, whereas liver necro-inflammatory lesions(A) were not
different (table). After adjustment on age and BMI, multivariate
analyses showed that menopause was associated with higher F score and
FPR, and that pregnancies were associated with lower FPR ; the effect
of oral contraceptives was not significant.
Conclusion: in women with CHC, menopause accelerates the liver
fibrosis progression. Such effect seems prevented by hormonal
substitution. Pregnancies may have a long-term beneficial impact on
liver fibrosis.
editorial note: a pilot study presented at the AASLD Single Conference
meeting in June 2001 showed HRT could improve response to HCV therapy
for postmenopausal women.
|
|
| http://www.natap.org/2001/aasld2/day29.htm |
|